Physician profile
Michael J Lobos
NPI 1750340287
$8,313.53
in general payments reported to CMS, 2019-2025
39 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,345 · 2020: $772 · 2021: $1,054 · 2022: $710 · 2023: $1,208 · 2024: $1,279 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.77 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,449.44 | 2019 | |
| Astellas Pharma US INC | $962.37 | 2019-2025 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $657.67 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $558.92 | 2020-2024 | Prolaris, Myrisk |
| Pfizer INC. | $517.88 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $487.78 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $425.78 | 2019-2025 | |
| Abbvie INC. | $392.16 | 2019-2025 | |
| Janssen Biotech, INC. | $360.30 | 2019-2025 | Erleada |
| Endo Pharmaceuticals INC. | $329.36 | 2019-2024 | Xiaflex, Aveed |
| Endo USA, INC. | $300.40 | 2024-2025 | Xiaflex, Aveed |
| Axonics, INC. | $286.14 | 2021-2023 | Axonics |
| Teleflex LLC | $254.85 | 2021-2024 | Urolift |
| Allergan, INC. | $169.31 | 2019-2021 | |
| Myovant Sciences INC. | $166.71 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lobos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.